港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响

Core Viewpoint - China Resources Pharmaceutical (03320) experienced a nearly 3% decline in stock price, currently trading at HKD 4.46, with a transaction volume of HKD 25.16 million. The company announced a profit forecast for its subsidiary, China Resources Boya Biopharmaceutical, indicating a significant drop in net profit for the fiscal year ending December 31, 2025, compared to the previous year [1]. Group 1 - China Resources Boya Biopharmaceutical expects a net profit attributable to shareholders of approximately RMB 105 million to RMB 136.5 million for the fiscal year ending December 31, 2025, down from RMB 397 million in the previous year [1]. - The company anticipates a net loss attributable to shareholders, excluding non-recurring gains and losses, of approximately RMB 7.5 million to RMB 15 million, compared to a net profit of RMB 302 million in the previous year [1]. - The blood products business of China Resources Boya Biopharmaceutical is facing challenges due to factors such as expanded centralized procurement, DRG/DIP reforms, medical insurance cost control, and stringent regulation of reasonable drug use, leading to a decrease in clinical prescriptions and demand [1]. Group 2 - Increased market competition has resulted in a year-on-year decline in the gross profit margin of China Resources Boya Biopharmaceutical's blood products business during the reporting period [1].